Cargando…

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer

BACKGROUND: Baseline health-related quality of life (QL) is associated with survival in advanced breast cancer. We sought to identify patients who were less likely to respond to chemotherapy and at greater risk of toxicity on the basis of their QL. METHODS: We used data from three advanced breast ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, C K, Stockler, M R, Coates, A S, Gebski, V, Lord, S J, Simes, R J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865758/ https://www.ncbi.nlm.nih.gov/pubmed/20389302 http://dx.doi.org/10.1038/sj.bjc.6605649

Ejemplares similares

Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone
por: Lee, Chee Khoon, et al.
Publicado: (2013)

Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer
por: Stockler, M R, et al.
Publicado: (2006)

The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study
por: Gormley, J A, et al.
Publicado: (2011)

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
por: von Plessen, C, et al.
Publicado: (2006)

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
por: Sjoquist, Katrin M., et al.
Publicado: (2022)

Clinical Benefit of Second-Line Palliative Chemotherapy in Advanced Soft-Tissue Sarcoma
por: Minchom, Anna, et al.
Publicado: (2010)

Carboplatin–paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort
por: Steinebrunner, Niels, et al.
Publicado: (2018)

Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?
por: Duric, V M, et al.
Publicado: (2005)

Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer
por: Lawrence, Nicola Jane, et al.
Publicado: (2018)

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer
por: Sharma, R, et al.
Publicado: (2006)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

Independent contributors to overall quality of life in people with advanced cancer
por: M Rodríguez, A, et al.
Publicado: (2013)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

Chemotherapy predictors and a time-dependent chemotherapy effect in metastatic esophageal cancer
por: Midthun, Lauren, et al.
Publicado: (2022)

10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection
por: Campbell, Ian, et al.
Publicado: (2023)

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer
por: Ackland, S P, et al.
Publicado: (2005)

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer
por: Meghal, Trishala, et al.
Publicado: (2019)

Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis
por: Verry, H, et al.
Publicado: (2012)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival
por: Wright, J D, et al.
Publicado: (2008)

Impact of AferBio® on quality of life and chemotherapy toxicity in advanced lung cancer patients (AFERBIO study): protocol study for a phase II randomized controlled trial
por: D’Almeida Preto, Daniel, et al.
Publicado: (2019)

A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)
por: Hall, P S, et al.
Publicado: (2017)

A systematic review of taxane-containing regimens for metastatic breast cancer
por: Ghersi, D, et al.
Publicado: (2005)

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas
por: Delpech, Y, et al.
Publicado: (2013)

Do patients with advanced breast cancer benefit from chemotherapy?
por: Ramirez, A. J., et al.
Publicado: (1998)

Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study
por: Zhang, A Y, et al.
Publicado: (2017)

Connexin 43 is an independent predictor of patient outcome in breast cancer patients
por: Chasampalioti, Maria, et al.
Publicado: (2018)

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy
por: Bernhard, J, et al.
Publicado: (2010)

Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer
por: Gusella, M, et al.
Publicado: (2009)

Aluminum in plant: Benefits, toxicity and tolerance mechanisms
por: Ofoe, Raphael, et al.
Publicado: (2023)

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
por: Bernhard, J, et al.
Publicado: (2008)

Genetic variants as predictors of toxicity and response in patients with non‐small cell lung cancer undergoing first‐line platinum‐based chemotherapy: Design of the multicenter PGxLUNG study
por: de Jong, Corine, et al.
Publicado: (2020)

Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy
por: Moastafa, Tarek M., et al.
Publicado: (2014)

Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2020)

Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
por: Spasic, Jelena, et al.
Publicado: (2022)

Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer
por: Poikonen, P, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_9cnnudve441cueabsdsgb2plmc